Oxiracetam – Forschung

The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis.

Perng CH, Chang YC, Tzang RF · Psychopharmacology (Berl) (2018)

A Meta-Analysis of Au/Polypropionic Acid Nanoparticles Loaded with Olacetam for the Treatment of Vascular Cognitive Impairment.

Yi Z, Liang W, Ruan W, Hua W, Lin X · J Nanosci Nanotechnol (2020)

Co-administration of Nanowired Oxiracetam and Neprilysin with Monoclonal Antibodies to Amyloid Beta Peptide and p-Tau Thwarted Exacerbation of Brain Pathology in Concussive Head Injury at Hot Environment

Einfach gesagt: Our previous experiments showed that nanowired delivery of oxiracetam significantly attenuated CHI-induced brain pathology and associated neurovascular changes.

Nozari A et al. · Advances in neurobiology (2023)

The efficacy and safety of post-stroke cognitive impairment therapies: an umbrella review.

Li Y, Cui R, Liu S, Qin Z, Sun W, Cheng Y · Front Pharmacol (2023)

Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders

Einfach gesagt: Based on calculations of the efficacy rates, our assessments indicate notable improvements in clinical outcomes with some of these agents.

Malykh AG et al. · Drugs (2010)

Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia.

Rozzini R, Zanetti O, Bianchetti A · Acta Neurol (Napoli) (1992)

Effects of acute doses of oxiracetam in the scopolamine model of human amnesia.

Preda L, Alberoni M, Bressi S, Cattaneo C, Parini J, Canal N · Psychopharmacology (Berl) (1993)

Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree.

Villardita C, Grioli S, Lomeo C, Cattaneo C, Parini J · Neuropsychobiology (1992)

Clinical efficacy and safety of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment.

Wang B, Zhong L, Qiao P, Ma Z · Pak J Pharm Sci (2020)

Double-blind, placebo-controlled, clinical, psychometric and neurophysiological investigations with oxiracetam in the organic brain syndrome of late life.

Saletu B, Linzmayer L, Grünberger J, Pietschmann H · Neuropsychobiology (1985)

Efficacy and safety of L-oxiracetam on cognitive function in patients with traumatic brain injury: a multicentre, randomised, double-blind, phase 3 clinical trial.

Liu T, Wang J, Zhao Z, Jiang W, Zhang M, Yu Y · Signal Transduct Target Ther (2025)

Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia.

Villardita C, Parini J, Grioli S, Quattropani M, Lomeo C, Scapagnini U · J Neural Transm Suppl (1987)

Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy.

Rozzini R, Zanetti O, Bianchetti A · Acta Neurol (Napoli) (1993)

Organic brain syndrome treated with oxiracetam. A double-blind randomized controlled trial.

Hjorther A, Browne E, Jakobsen K, Viskum P, Gyntelberg F · Acta Neurol Scand (1987)

Oxiracetam in dementia: a double-blind, placebo-controlled study.

Bottini G, Vallar G, Cappa S, Monza GC, Scarpini E, Baron P · Acta Neurol Scand (1992)

Selegiline versus oxiracetam in patients with Alzheimer-type dementia.

Falsaperla A, Monici Preti PA, Oliani C · Clin Ther (1990)

Double-blind placebo-controlled, neuropsychological and neurophysiological investigations with oxiracetam (CGP 21690E) in memory-impaired patients with epilepsy.

Aldenkamp AP, van Wieringen A, Alpherts WC, van Emde Boas W, Haverkort HA, de Vries J · Neuropsychobiology (1990)

Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: A multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial.

Lim JS, Lee J, Kang Y, Park HT, Kim DE, Cha JK · Contemp Clin Trials (2023)

Oxiracetam and physical activity in preventing cognitive decline after stroke: A multicenter, randomized controlled trial.

Lim JS, Rha JH, Park JH, Lee K, Chang DI, Heo SH · Eur Stroke J (2026)

Activity of oxiracetam in patients with organic brain syndrome: a neuropsychological study.

Moglia A, Sinforiani E, Zandrini C, Gualtieri S, Corsico R, Arrigo A · Clin Neuropharmacol (1986)